Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study
Naoki Kashihara(Kawasaki Medical School), Yukio Tomioka(Zeria Pharmaceutical (Japan)), Takayuki Ishii(Kanazawa University), Yuko Taniguchi(Nagase ChemteX (Japan)), Hidetoshi Kanai(Kokura Memorial Hospital), Yoko Kaneko(Keio University), Yasuro Kumeda(Osaka Hospital), Yorihiko Higashino(Sakurabashi Watanabe Hospital), Yoshitaka Maeda(JA Toride Medical Center)
Cited by 3
Related Papers
NAK is an IκB kinase-activating kinase
|Nature|2000|374
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
|Nephrology Dialysis Transplantation|2019|216
Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms
|Retrovirology|2005|199
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|Nephrology Dialysis Transplantation|2020|189
Identification of NAP1, a Regulatory Subunit of IκB Kinase-Related Kinases That Potentiates NF-κB Signaling
|Molecular and Cellular Biology|2003|162